Sign In
Buy SGYP
$0.0064
+0 (+0%)
At Close: Sep 17, 2019
Synergy Pharmaceuticals to Report First Quarter 2018 Financial Results and Host Conference Call and Webcast
08:30am, Wednesday, 25'th Apr 2018
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today anno
Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update
04:20pm, Thursday, 01'st Mar 2018
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today repo
Synergy Pharmaceuticals Achieves Cash Balance Requirement to Access Additional Capital
08:00am, Thursday, 01'st Feb 2018
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today ann
Synergy Pharmaceuticals to Report Third Quarter 2017 Financial Results and Host Conference Call and Webcast
08:30am, Wednesday, 01'st Nov 2017
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced it intends to release third quarter 2017 financial results after the NASDAQ market close on Thursday, November 9,
Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results and Business Update
04:30pm, Wednesday, 09'th Aug 2017
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today repo
